These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16845646)

  • 1. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study.
    Gabriel A
    Depress Anxiety; 2006; 23(8):485-8. PubMed ID: 16845646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability.
    Ivković M; Damjanović A; Jovanović A; Cvetić T; Jasović-Gasić M
    Psychiatr Danub; 2009 Jun; 21(2):187-93. PubMed ID: 19556947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study.
    Schindler F; Anghelescu IG
    Int Clin Psychopharmacol; 2007 May; 22(3):179-82. PubMed ID: 17414745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament.
    Manning JS; Haykal RF; Connor PD; Cunningham PD; Jackson WC; Long S
    J Affect Disord; 2005 Feb; 84(2-3):259-66. PubMed ID: 15708424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): An open label naturalistic study.
    Gabriel A
    Clin Ter; 2011; 162(2):113-8. PubMed ID: 21533316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive lamotrigine therapy for patients with bipolar II depression partially responsive to mood stabilizers.
    Chang JS; Moon E; Cha B; Ha K
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1322-6. PubMed ID: 20673782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
    J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
    Nierenberg AA; Ostacher MJ; Calabrese JR; Ketter TA; Marangell LB; Miklowitz DJ; Miyahara S; Bauer MS; Thase ME; Wisniewski SR; Sachs GS
    Am J Psychiatry; 2006 Feb; 163(2):210-6. PubMed ID: 16449473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
    Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
    Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression.
    McElroy SL; Zarate CA; Cookson J; Suppes T; Huffman RF; Greene P; Ascher J
    J Clin Psychiatry; 2004 Feb; 65(2):204-10. PubMed ID: 15003074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) for mood disorders: double-blind, placebo-controlled studies.
    Zhang ZJ; Kang WH; Li Q; Tan QR
    J Psychiatr Res; 2007 Nov; 41(10):828-36. PubMed ID: 17010995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study.
    Pae CU; Jeon HJ; Lee BC; Seo HJ; Kim SG; Park EJ; Kim W; Kwak KP; Han C; Cho SJ; Hahn SW; Jon DI; Choi JH; Jun TY
    Int Clin Psychopharmacol; 2013 Nov; 28(6):322-9. PubMed ID: 23873293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.